Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care in ophthalmology with the aspiration of developing functional cures to restore vision and prevent blindness. Adverum leverages its proprietary intravitreal platform, to develop a novel gene therapy candidate, Ixo-vec, as a one-time, in-office, injection for patients with nAMD. Adverum aspires to transform the stands of care, Preserve Sight For Life®, and create a profound societal impact around the globe.
